The estimated Net Worth of James W Jr Traweek is at least $528 Миллион dollars as of 18 November 2019. James Traweek owns over 40,218 units of Reata Pharmaceuticals Inc stock worth over $528,036,408 and over the last 8 years James sold RETA stock worth over $0.
James has made over 19 trades of the Reata Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently James bought 40,218 units of RETA stock worth $7,359,894 on 18 November 2019.
The largest trade James's ever made was buying 308,220 units of Reata Pharmaceuticals Inc stock on 16 August 2016 worth over $5,264,398. On average, James trades about 92,529 units every 55 days since 2016. As of 18 November 2019 James still owns at least 3,063,567 units of Reata Pharmaceuticals Inc stock.
You can see the complete history of James Traweek stock trades at the bottom of the page.
James's mailing address filed with the SEC is C/O CPMG, INC., 2000 MCKINNEY AVE., SUITE 2125, DALLAS, TX, 75201.
Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy и Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include: